Endocrine therapy in breast cancer / edición, William R. Miller, James N. Ingle.

Incluye referencias bibliográficas.

Part I. Introduction.--
1. Why Endocrine Therapy? / Daniel F. Haves.--

Part II. Advanced Breast Cancer.--
2. Tamoxifen and Advanced Breast Cancer: An Overview / John F. Forbes.--
3. Overview of Aromatase Inhibitors and Inactivators in the Treatment of Advanced Breast Cancer / Per Eystein Lønning.--
4. Endocrine Treatment of Advanced Breast Cancer: Selective Estrogen-Receptor Modulators (SERMS) / Stephen R. D. Johnston and Anthony Howell.--
5. Other Endocrine and Biological Agents in the Treatment of Advanced Breast Cancer / Jan G. M. Klijn, Els M. J. J. Berns, and John A. Foekens.--
Panel Discussion 1: Advanced Breast Cancer / Manfred Kaufmann and Henning T. Mouridsen, Chairmen.--

Part III. Early Breast Cancer.--
6. Early Breast Cancer: Tamoxifen Overview / Carsten Rose.--
7. Aromatase Inhibitors and Early Breast Cancer / Paul E. Goss.--
8. SERMS: Overview in Early Breast Cancer / lan E. Smith.--
9. Surrogate and Intermediate Markers in Early Breast Cancer / Mitch Dowsett.--
Panel Discussion 2: Early Breast Cancer / Hans-Jorg Senn and William R. Miller, Chairmen.--

Part IV. Neoadjuvant Therapy.--
10. Neoadjuvant Endocrine Therapy for Breast Cancer: A Medical Oncologist's Perspective / Matthew J. Ellis.--
11. Neoadjuvant Therapy: Surgical Perspectives / J. Michael Dixon.--
12. Pathology of Breast Cancer Following Neoadjuvant Endocrine Therapy / Hironobu Sasano, Takashi Suzuki, and Takuya Moriya.--
13. Neoadjuvant Therapy: Prediction of Response / William R. Miller, T. J. Anderson, S. Iqbal, and J. Michael Dixon.--
14. Mechanisms of Resistance to Endocrine Therapy / Nancy E. Hynes.--
Panel Discussion 3: Neoadjuvant Therapy / James N. Ingle and Ian E. Smith, Chairmen.--

Part V. Chemoprevention.--
15. Epidemiological Basis of Hormonal Chemoprevention of Breast Cancer / Malcolm C. Pike, John R. Daniels, and Darcy V. Spicer.--
16. Breast Carcinogenesis and Its Prevention by Inhibition of Estrogen Genotoxicity / Joachim G. Liehr.--
17. Use of Selective Antiestrogens for the Chemoprevention of Breast Cancer / Trevor J. Powles.--
18. Aromatase Inhibitors and Chemoprevention of Breast Cancer / Paul E. Goss.--
Panel Discussion 4: Chemoprevention / Christopher C. Benz and Anthony Howell, Chairmen.--

Part VI. Conclusion.--
Panel Discussion 5: Final Discussion and Wrap-Up / James N. Ingle and Ajay Bhatnagar, Chairmen.

This reference evaluates and describes the latest strategies for hormone suppression and blockade in the management of early and advanced stage breast cancer and explores the effects of tamoxifen, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and their combination on both breast cancers and normal tissues. Endocrine Therapy in Breast Cancer ·details modern techniques for molecular profiling, monitoring, and targeting ·offers methods to identify high-risk groups ·evaluates molecular biomarkers in breast cancer assessment ·examines the potential toxicity of estrogen receptor (ER)-directed endocrine therapy ·investigates the development of endocrine resistance ·discusses neoadjuvant and preoperative approaches in patient care ·reviews mechanisms that lead to estrogen-independent phenotypes Surveying the medical, surgical, and pathological aspects of endocrine therapy, as well as future research opportunities, Endocrine Therapy in Breast Cancer is a concise and in-depth manual for medical, surgical, and radiation oncologists; endocrinologists; gynecologists; obstetricians; pharmacologists; family physicians; reproductive biologists; epidemiologists; and medical school students.

Área de Ciencias de la Salud